학술논문
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Document Type
Article
Author
Short, N.J.; Muftuoglu, M.; Ong, F.; Nasr, L.; Macaron, W.; Montalban-Bravo, G.; Alvarado, Y.; Basyal, M.; Daver, N.; Dinardo, C.D.; Borthakur, G.; Jain, N.; Ohanian, M.; Jabbour, E.; Issa, G.C.; Bose, P.; Ravandi, F.; Delumpa, R.; Abramova, R.; Garcia-Manero, G.; Andreeff, M.; Kantarjian, H.; Qiao, W.; Huang, X.; Kanagal-Shamanna, R.; Patel, K.P.; Cortes, J.
Source
In: Journal of Hematology and Oncology . (Journal of Hematology and Oncology, December 2023, 16(1))
Subject
Language
English
ISSN
17568722